祥生医疗(688358) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was RMB 44,734.89 million, a decrease of 4.55% compared to the previous year[4] - Net profit attributable to shareholders was RMB 11,663.05 million, down 16.99% year-on-year[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 10,335.66 million, a decline of 18.69% from the previous year[4] - Basic earnings per share decreased to RMB 1.04, down 17.46% compared to the same period last year[4] - The decline in net profit was primarily due to a decrease in revenue and foreign exchange losses caused by fluctuations in the US dollar exchange rate[7] Assets and Equity - Total assets at the end of the reporting period were RMB 159,872.47 million, an increase of 0.11% year-on-year[4] - Shareholders' equity attributable to the parent company was RMB 138,376.77 million, a decrease of 2.59% from the previous year[4] - The weighted average return on net assets was 8.30%, a decrease of 1.83 percentage points compared to the previous year[4] Financial Data Caution - The company emphasizes that the financial data is preliminary and subject to final confirmation in the annual report[5] - Investors are advised to be cautious regarding investment risks due to the preliminary nature of the financial data[8]